Domperidone for Relief of Gastrointestinal Disorders

Stopped early · Not applicable

Conditions studied: Gastroparesis, GERD, Esophagitis, Dyspepsia, Chronic Idiopathic Constipation, Nausea, Vomiting

In brief

The purpose of this study is to make Domperidone available to patients with gastrointestinal disorders who have failed standard therapy and who might benefit from it.

Key facts

Study ID

NCT00761254

Run by

Carle Physician Group

People needed

42

Starts

2008-08-01

Expected to finish

2012-09-01

Last updated by the study team

2012-09-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older
• symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms, gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that is refractory to standard therapy
• subjects must have a comprehensive evaluation to eliminate other causes of their symptoms.

You may not qualify if…

• history of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation, and Torsade de pointes. Subjects with minor forms of ectopy (PACs) are not necessarily excluded.
• clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged QTc (QTc > 450 milliseconds for males, QTc > 470 milliseconds for females.)
• clinically significant electrolyte disorders.
• gastrointestinal hemorrhage or obstruction.
• presence of a prolactinoma (prolactin-releasing pituitary tumor.)
• pregnant or breast feeding female.
• known allergy to Domperidone.

Where it is running

• Carle Health Care Incorporated d/b/a Carle Physician Group — Urbana, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.